Your browser doesn't support javascript.
loading
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Carras, Sylvain; Torroja, Alexia; Emadali, Anouk; Montaut, Emilie; Daguindau, Nicolas; Tempescul, Adrian; Moreau, Anne; Tchernonog, Emmanuelle; Schmitt, Anna; Houot, Roch; Dartigeas, Caroline; Barbieux, Sarah; Corm, Selim; Banos, Anne; Fouillet, Ludovic; Dupuis, Jehan; Macro, Margaret; Fleury, Joel; Jardin, Fabrice; Sarkozy, Clementine; Damaj, Ghandi; Feugier, Pierre; Fornecker, Luc Matthieu; Chabrot, Cecile; Dorvaux, Veronique; Bouabdallah, Krimo; Amorim, Sandy; Garidi, Reda; Voillat, Laurent; Joly, Bertrand; Morineau, Nadine; Moles, Marie Pierre; Zerazhi, Hacene; Fontan, Jean; Arkam, Yazid; Alexis, Magda; Delwail, Vincent; Vilque, Jean Pierre; Ysebaert, Loic; Burroni, Barbara; Callanan, Mary; Le Gouill, Steven; Gressin, Rémy.
Afiliação
  • Carras S; Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Molecular biology department; Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Oncohema
  • Torroja A; Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Oncohematology department.
  • Emadali A; Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Research and innovation unit.
  • Montaut E; Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Research and innovation unit.
  • Daguindau N; Hematology Department Annecy hospital.
  • Tempescul A; Hematology Unit, Brest University Hospital, Brest France.
  • Moreau A; Pathology Department, University Hospital, Nantes.
  • Tchernonog E; Hematology Department, University Hospital, Montpellier.
  • Schmitt A; Hematology Department, Cancerology Institute Bergonie, Bordeaux.
  • Houot R; Hematology Department, University Hospital, Rennes.
  • Dartigeas C; Hematology Department, University Hospital, Tours.
  • Barbieux S; Hematology Department, Dunkerque Hospital.
  • Corm S; Hematology Department, Chambery.
  • Banos A; Hematology Department, Bayonne Cote Basque Hospital.
  • Fouillet L; Hematology Department, University Hospital, Saint Etienne.
  • Dupuis J; Lymphoid malignancies Unit, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil.
  • Macro M; IHBN - Hematology Department, University Hospital, Caen.
  • Fleury J; Hematology Department, Cancerology Institute, Clermont-Ferrand.
  • Jardin F; Hematology Department, Centre Henri Becquerel, Rouen.
  • Sarkozy C; Institut Curie, Paris and Paris Saint Quentin University, UVSQ.
  • Damaj G; Hematology Department, University Hospital, Caen.
  • Feugier P; Hematology Department, University Hospital, Nancy.
  • Fornecker LM; Hematology Department, University Hospital, Strasbourg.
  • Chabrot C; Hematology Department, University Hospital, Clermont-Ferrand.
  • Dorvaux V; Hematology Department, University Hospital, Metz.
  • Bouabdallah K; Hematology Department, University Hospital, Bordeaux, Bordeaux.
  • Amorim S; Hematology and cellular therapy Department, Hospital Saint Vincent de Paul, Université catholique de Lille.
  • Garidi R; Hematology Department, Hospital Saint Quentin.
  • Voillat L; Hematology Department, Hospital Chalon sur Saone.
  • Joly B; Hematology Department, Corbeil Hospital.
  • Morineau N; Hematology department, Hospital La Roche Sur Yon.
  • Moles MP; Hematology Department, University Hospital Angers.
  • Zerazhi H; Hematology Department, Avignon Hospital.
  • Fontan J; Hematology Department, University Hospital, Besançon.
  • Arkam Y; Hematology Department, Mulhouse Hospital.
  • Alexis M; Hematology Department, Orleans Hospital.
  • Delwail V; Onco-Hematology Department, University Hospital Poitiers and INSERM, CIC 1402, University of Poitiers.
  • Vilque JP; Hematology Department, Cancer Center Baclesse Caen.
  • Ysebaert L; Institut universitaire du cancer de Toulouse Oncopole.
  • Burroni B; Assistance Publique - Hôpitaux de Paris (APHP), Hôpital Cochin, Department of Pathology; Centre de Recherche des Cordeliers, Sorbonne University, Inserm, UMRS 1138, Université Paris Cité, F-75006 Paris.
  • Callanan M; Unit For Innovation in Genetics and Epigenetics and Oncology. Dijon University Hospital.
  • Le Gouill S; Institut Curie, Paris and Paris Saint Quentin University, UVSQ.
  • Gressin R; Univ. Grenoble Alpes. University Hospital, Grenoble France, Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309, UGA), Oncohematology department.
Haematologica ; 2023 Nov 30.
Article em En | MEDLINE | ID: mdl-38031755
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article